Ann: Positive new DMD Combination Therapy Data in mdx mice, page-7

What a fantastic read. And patent protected to 2044. Well done ANP.

Families can now be confident that even if their son has received the one off gene therapy treatment, their so can still benefit from ATL1102. This is real hope, something these families haven't had prior to this.

For ANP holders it means ATL 1102 has potential for 100% of DMD boys, once non-ambulant and ambulant cohorts are cleared.

Perhaps starting ATL1102 at an earlier age, like the gene therapy, could prevent fibrosis damage from starting?

Awesome news for DMD families.

I see a couple of old hands havevdaid they wont participate in the SPP, but I think this will attract many other holders. Roll back probably a certainty now.